Roivant Sciences Eric Venker sells 200,000 shares

Roivant Sciences Ltd.'s President & Immunovant CEO made the sale under a Rule 10b5-1 trading plan adopted on March 28, 2025.

Rhea-AI Filing Summary

Roivant Sciences Ltd. officer Eric Venker, whose title is President & Immunovant CEO, exercised options for 200,000 common shares at a $3.85 per-share exercise price and sold 200,000 common shares on September 30, 2026. The shares were sold at a weighted average price of $36.62 per share in multiple transactions ranging from $36.49 to $36.76; the sales were made under a Rule 10b5-1 trading plan adopted on March 28, 2025. After the exercise, the reported direct stock-option position was 3,644,834 shares.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 200,000 shs ($7.32M)

Approx. gross sale proceeds $7.32M

Approx. exercise cost $770K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F2	200,000	$0.00	$0.00
Exercise	Common Shares	200,000	$3.85	$770K
Sale	Common Shares F1	200,000	$36.62	$7.32M

Holdings After Transaction: Stock Option (Right to Buy) — 3,644,834 contracts (Direct); Common Shares — 1,599,154 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
2. F2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options exercised: 200,000 shares Exercise price: $3.85 per share Common shares sold: 200,000 shares +3 more

6 metrics

Options exercised 200,000 shares September 30, 2026

Exercise price $3.85 per share Options exercised on September 30, 2026

Common shares sold 200,000 shares September 30, 2026

Weighted average sale price $36.62 per share Sale on September 30, 2026

Sale price range $36.49 to $36.76 per share Multiple sale transactions

Direct stock-option position after transaction 3,644,834 shares Reported following the September 30, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested, Stock Option (Right to Buy)

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"stock options to purchase Common Shares that is fully vested"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did Eric Venker sell, and at what price?

Eric Venker sold 200,000 common shares on September 30, 2026, at a weighted average price of $36.62 per share. The sales occurred in multiple transactions at prices ranging from $36.49 to $36.76 under a Rule 10b5-1 trading plan adopted on March 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 05:38 PM Accepted by SEC EDGAR 10/02/2026 - 05:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/30/2026		M		200,000	A	$3.85	1,799,154	D
Common Shares	09/30/2026		S		200,000	D	$36.62(1)	1,599,154	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	09/30/2026		M			200,000	(2)	04/19/2032	Common Stock	200,000	$0	3,644,834	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Eric Venker	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)